Advanced search
Publication Cover
HIV Clinical Trials Volume 10, 2009 - Issue 6
Submit an article Journal homepage
90
Views
42
CrossRef citations to date
0
Altmetric
Original Articles

Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study)

Estevão P. NunesProjeto Praça Onze Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilCorrespondence[email protected] ocruz.br
,
Marilia Santini de OliveiraSetor de DST/AIDS Hospital Geral de Nova Iguaçu, Rio de Janeiro, Brazil
,
Monica MerçonProjeto Praça Onze Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
,
Roberto ZajdenvergProjeto Praça Onze Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
,
Jose Claudio FaulhaberProjeto Praça Onze Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
,
José Henrique PilottoSetor de DST/AIDS Hospital Geral de Nova Iguaçu, Rio de Janeiro, Brazil
,
Jorge Eurico RibeiroSetor de DST/AIDS Hospital Geral de Nova Iguaçu, Rio de Janeiro, Brazil
,
Michael NortonAbbott Laboratories Linden, New Jersey, USA
&
Mauro SchechterProjeto Praça Onze Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
 show all
Pages 368-374 | Published online: 06 Jan 2015

REFERENCES

  • Delfraissy JF, Flandre P, Delaugerre C, et al. MONARK trial (MONotherapy AntiRetroviral Kaletra): lopinavir/ritonavir (LPV/r) monotherapy or plus zidovudine and lamivu-dine in antiretroviral-naive HIV infected patients. AIDS. 2008;22:385–393.
  • Campo RE, Lalanne R, Tanner TJ, et al. Lopinavir/ritonavir maintenance monotherapy after successful viral suppres-sion with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2005;19:447–449.
  • Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleo-sides for maintenance therapy of HIV: 96-week results. J Acquir Immune Defic Syndr 2009;51:142–157.
  • Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral sup-pression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005;40:280–287.
  • Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clini-cal Trials Group (AACTG). AIDS Care. 2000;12:255–266.
  • Badri M, Ehrlich R, Pulerwitz T, et al. Tuberculosis should not be considered an AIDS-defining illness in areas with a high tuberculosis prevalence. Int J Tuberc Lung Dis. 2002 ;6(3):231–237.
  • Sprinz E, Bay MB, Lazzaretti RK, et al. Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil. HIV Med. 2008;9:270–276.
  • Cameron W, da Silva BA, Arribas J, et al. A 96-week com-parison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combi-nation therapy. J Infect Dis. 2008;198:234–240.
  • Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS. 2009; 23(3):279–291.
  • Vergara TR, Estrela RC, Suarez-Kurtz G, et al. Limited penetra-tion of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil. Ther Drug Monitor 2006;28:175–179.
  • Vernazza P, Daneel S, Schiffer V, et al. The role of com-partment penetration in PI-monotherapy: the Atazanayir-Ritonayir Monomaintenance (ATARITMO) Trial. AIDS. 2007;21:1309–1315.
  • Sahali S, Chaix M, Delfraissy JF, et al. Ritonavir-boosted protase inhibitor monotherapy for the treatment of HIV-1 infection. AIDS Rev. 2008;10: 4–14.
  • Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639): 646–655.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.